{"name":"Oryx GmbH & Co. KG","slug":"oryx-gmbh-co-kg","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"P16_37-63 peptide without Montanide® ISA-51 VG","genericName":"P16_37-63 peptide without Montanide® ISA-51 VG","slug":"p16-37-63-peptide-without-montanide-isa-51-vg","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"P16_37-63 peptide without Montanide® ISA-51 VG","genericName":"P16_37-63 peptide without Montanide® ISA-51 VG","slug":"p16-37-63-peptide-without-montanide-isa-51-vg","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxQSmcxVmU2cEM5MEFoREVfVGswRUJ4c2tQMTR4MVJ3SkxBdklHRmtqaXNLRjdiOTd5eGxjM2FWX2RxZF9XZGRaMTVXNG5XRlVtaTNKUkZMem1LM1VpRG9NdkVyMk1QVXRtYmhEaTR1bTRnY3hsWkVfa3NuNnNZNEV2TnJ0eFZZUmZfY25HTlV0ZlZoLXFPVmJWUmhjS0RGNm9NOEt4VFhjTEluaUpUdmJLcmg4Tmp0V3lnZ2hHRkExbkpxU2plc2FCb0x4TWpCQ2xUb0lNYXBrYnBheVJVcndJ?oc=5","date":"2020-04-13","type":"earnings","source":"BioSpace","summary":"Sales Revenue in the Oncolytic Virus Immunotherapy Market to Witness Growth at Robust CAGR 12% During 2019 to 2029 - BioSpace","headline":"Sales Revenue in the Oncolytic Virus Immunotherapy Market to Witness Growth at Robust CAGR 12% During 2019 to 2029","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}